Race to stop Cancer's return: two drugs face off in major blood cancer trial
NCT ID NCT07463651
Summary
This study aims to find the best maintenance therapy to prevent cancer from returning in patients with a specific genetic type of acute myeloid leukemia (AML) who have received a stem cell transplant. Researchers will compare two drugs, gilteritinib and sorafenib, given for two years after transplant to nearly 600 patients. The study uses an ultra-sensitive blood test to detect even tiny amounts of leftover cancer cells and see which drug better keeps the disease away.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
the First Affiliated Hosptital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.